创投集团合作子基金投资企业药捷安康在港交所成功上市

Core Viewpoint - The company Yaojie Ankang (Nanjing) Technology Co., Ltd. has officially listed on the Hong Kong Stock Exchange under the stock code 2617.HK, raising approximately HKD 200 million, attracting significant attention from the capital market with cornerstone investors including Jiangbei Pharmaceutical and Kangfang Biotech [1][3]. Company Overview - Yaojie Ankang is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule innovative therapies for oncology, inflammation, and cardiovascular metabolic diseases. The company has established a pipeline of six clinical-stage candidates and one preclinical candidate, with plans for continuous expansion [3]. - The core product, Tinengotinib (TT-00420), is a unique multi-target kinase (MTK) inhibitor currently in registration clinical trials for cholangiocarcinoma (CCA) patients who have experienced disease progression after prior FGFR inhibitor treatment, with trials being conducted in both China and internationally [3]. Investment Background - The Zijin Advanced Manufacturing Fund, which invested in Yaojie Ankang, has witnessed the company's growth and development. The fund, established in 2018 with a scale of RMB 500 million, focuses on advanced manufacturing and related service industries, investing in key sectors such as rail transportation equipment, high-end ships, industrial robots, and high-end medical devices [4]. - The fund aims to explore quality investment opportunities in strategic emerging industries like biomedicine, contributing to industrial upgrading and innovative development [4].